Q-omics provides the consensus-scored LINC02694 profile across patient tissues and cancer cell-line models. LINC02694 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LINC02694 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, LINC02694 RNA expression shows 9,581 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KIRC, and TGCT as cancer lineages where LINC02694 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02694 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02694 survival associations across molecular data types. LINC02694 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02694 RNA expression–survival associations across cancer types. High LINC02694 expression shows unfavorable associations in UVM, LGG and UCS, but favorable associations in BLCA, HNSC and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for LINC02694 RNA expression.
This table summarizes LINC02694 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02694. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02694 shows lower tumor expression in LUSC and higher tumor expression in KIRC, THCA, STAD, BRCA and LIHC. The KIRC box plot shows higher LINC02694 RNA expression in tumor versus normal tissue (log2 FC = +0.119, t-test p < 0.001).
This table shows molecular features associated with LINC02694 in patient tissues and cancer cell lines. In patient samples, LINC02694 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC02694 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
